Nektar Therapeutics
NKTR
166 hedge funds and large institutions have $1.55B invested in Nektar Therapeutics in 2015 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 70 increasing their positions, 51 reducing their positions, and 35 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 51
3% more call options, than puts
Call options by funds: $3.66M | Put options by funds: $3.54M
8% less funds holding
Funds holding: 181 → 166 (-15)
10% less capital invested
Capital invested by funds: $1.73B → $1.55B (-$176M)
40% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 35
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| 1 |
Millennium Management
New York
|
+$42.9M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$11.6M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$8.84M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$7.76M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.88M |
Top Sellers
| 1 |
GAM
Gotham Asset Management
New York
|
-$17.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.13M |
| 3 |
D.E. Shaw & Co
New York
|
-$6.58M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$6.21M |
| 5 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$5.75M |
NKTR Hedge Fund Activity: Q3 2015 in Review
166 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2015, worth a combined $1.55B — down 10% from $1.73B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of NKTR and 21 opened new positions — a net loss of 14 holders — while 51 trimmed existing stakes and 70 added.
The largest buyer was Millennium Management, adding an estimated $42.9M. The largest seller was Gotham Asset Management, exiting entirely with an estimated $17.1M sold.
- 166 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2015, down from 181 in Q2 2015.
- Funds reported $1.55B of Nektar Therapeutics stock for Q3 2015, down 10% quarter-over-quarter.
- 21 funds opened new Nektar Therapeutics positions in Q3 2015 and 35 closed out, a net change of -14 holders.
- The largest Nektar Therapeutics buyer in Q3 2015 was Millennium Management, an estimated $42.9M added.
- The largest Nektar Therapeutics seller in Q3 2015 was Gotham Asset Management, an estimated $17.1M sold.
Based on aggregated 13F filings for Q3 2015.